全球树突细胞癌症疫苗市场规模（按产品类型、最终用户、区域范围）预测（至 2025 年）

树突细胞癌症疫苗市场规模及预测

预计2024年树突状细胞癌疫苗市场规模将达到24.1亿美元，到2032年将达到51.8亿美元，2026年至2032年的复合年增长率为10.5%。

• 树突状细胞帮助免疫系统辨识并清除异常细胞，包括癌细胞。为了研发疫苗，科学家在实验室中将树突细胞与癌细胞一起培养，以刺激人体免疫系统对抗恶性肿瘤。
• II 期研究表明，树突状细胞免疫增加了浸润肿瘤的淋巴细胞数量，引发了免疫反应，并可能提高某些患者的整体存活率。
• 此疫苗利用β细胞蛋白和患者自身的免疫细胞（树突状细胞）。透过指示免疫系统攻击β细胞，疫苗可能有助于β细胞自癒并产生足够的胰岛素来调节血糖值。
• 转移性前列腺癌、肾细胞癌、神经胶质瘤和黑色素瘤等几种肿瘤都是树突状细胞癌症疫苗临床试验的对象。

全球树突细胞癌症疫苗市场动态

影响全球树突细胞癌疫苗市场的关键市场动态：

关键市场驱动因素

• 癌症发生率不断上升：癌症已成为全球严重的公共卫生问题，每年新增数百万例癌症病例。癌症发生率的不断上升，很大程度上推动了诸如树突状细胞癌症疫苗等新型有效治疗方法的研发。
• 免疫疗法的应用范围扩大：免疫疗法是一种刺激免疫系统对抗癌细胞的癌症治疗方法。树突细胞疫苗是临床试验中展现出良好前景的免疫疗法。随着免疫疗法的普及，预计对树突状细胞癌症疫苗的需求将会增加。
• 技术进步：技术进步使得更精准、更有效的树突细胞癌症疫苗成为可能。例如，科学家正在开发分离和刺激树突状细胞的新方法，以及如何将树突细胞疫苗输送到体内。
• 增加研发支出：製药公司和政府机构正在大力投资树突细胞癌疫苗的研发。预计这项投资将在未来几年带来新的、改进的疫苗。

主要挑战

• 製造复杂性：树突状细胞癌症疫苗的製造过程包括提取患者自身的免疫细胞，在实验室中进行改造以靶向癌症，然后将免疫细胞重新註入患者体内。疫苗製造过程复杂，成本高且耗时。
• 疗效有限：儘管一些研究显示出令人鼓舞的结果，但树突状细胞癌疫苗已被证明对多种癌症类型不是一种可靠的治疗方法。为了提高这些疫苗的有效性，研究人员正在尝试改进其生产流程。
• 技术进步树突细胞癌疫苗市场受到技术进步的推动。个人化疫苗接种和识别最有可能从该治疗方法中受益的患者正在受到人工智慧 (AI) 的推动。此外，基因组学能够识别最佳肿瘤标靶，从而开发更有效的疫苗。人工智慧还可以简化复杂的生产流程，使其成本更低、更易于取得。技术进步的融合为开发强效的客製化树突状细胞癌疫苗打开了大门。

主要趋势

• 抗原发现：基因组定序有助于发现肿瘤特异性抗原，即诱导免疫反应的化学物质。人工智慧可以分析和预测这些抗原刺激免疫系统的能力，从而实现更精准的疫苗研发。
• 肿瘤异质性：即使是同一种癌症的患者，其肿瘤基因组成也会有所不同，这增加了对树突状细胞癌症疫苗的需求。
• 整合专业知识：新兴企业通常拥有尖端技术或独特的抗原靶点，而现有企业则提供生产、监管流程和临床试验的知识。整合各方技能可以克服各自的局限性，加速疫苗研发。

目录

第一章 树突细胞癌症疫苗的全球市场介绍

• 市场概览
• 研究范围
• 先决条件

第二章执行摘要

第三章：已验证的市场研究调查方法

• 资料探勘
• 验证
• 第一手资料
• 资料来源列表

第四章 树突细胞癌症疫苗的全球市场预测

• 概述
• 市场动态
  • 驱动程式
  • 限制因素
  • 机会
• 波特五力模型
• 价值链分析

5. 全球树突细胞癌症疫苗市场（依产品类型）

• 概述
• Sipuleucel-T
• CreaVax

第六章全球树突细胞癌症疫苗市场（依最终用户）

• 概述
• 孩子们
• 成人

7. 全球树突细胞癌症疫苗市场（按地区）

• 概述
• 北美洲
  • 美国
  • 加拿大
  • 墨西哥
• 欧洲
  • 德国
  • 英国
  • 法国
  • 其他欧洲国家
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 其他亚太地区
• 世界其他地区
  • 拉丁美洲
  • 中东和非洲

第八章树突细胞癌疫苗市场的全球竞争格局

• 概述
• 各公司市场排名
• 主要发展策略

第九章 公司简介

• GlaxoSmithKline plc
• 3M Company
• Activartis
• Batavia Bioservices
• Argos Therapeutics
• Sanpower Corporation
• Elios Therapeutics
• DanDrit Biotech
• DCPrime
• ImmunoCellular Therapeutics

第十章 重大进展

• 产品发布/开发
• 合併与收购
• 业务扩展
• 伙伴关係与合作

第十一章 附录

• 相关调查

Dendritic Cell Cancer Vaccine Market Size And Forecast

Dendritic Cell Cancer Vaccine Market size was valued at USD 2.41 Billion in 2024 and is projected to reach USD 5.18 Billion by 2032, growing at a CAGR of 10.5% from 2026-2032.

• Dendritic cells aid the immune system in identifying and eliminating aberrant cells, including cancerous cells. Scientists cultivate dendritic cells alongside cancer cells in the lab in order to create the vaccine. Our immune system is then prompted to combat the malignancy by the vaccine.
• In phase II studies, it was demonstrated that dendritic cell immunization might boost the number of lymphocytes invading tumors, trigger an immune response, and improve overall survival for a subset of patients.
• A beta-cell protein and the patient's own immune cells, known as dendritic cells, are used to make the vaccine. The vaccination may help the beta-cells heal and produce adequate insulin to regulate blood sugar levels by instructing the immune system to attack on beta-cells.
• Multiple tumors, including metastatic prostate cancer, renal cell carcinoma, glioma, and melanoma, have been subjected to a clinical trial of the Dendritic Cell Cancer Vaccination.

Global Dendritic Cell Cancer Vaccine Market Dynamics

The key market dynamics that are shaping the global Dendritic Cell Cancer Vaccine Market include:

Key Market Drivers:

• Growing Cancer Prevalence: With millions of new cases reported each year, cancer is a serious public health concern on a global scale. The creation of novel and efficient therapies, such as dendritic cell cancer vaccines, is largely fueled by the rising prevalence of cancer.
• Expanding Use of Immunotherapy: Immunotherapy is a cancer treatment that stimulates the immune system to combat cancer cells. One type of immunotherapy that has shown potential in clinical trials is the use of dendritic cell vaccines. Dendritic cell cancer vaccine demand is predicted to increase as immunotherapy gains traction.
• Technology Advancements: More precise and potent dendritic cell cancer vaccines are now possible because due to technological advancements. For instance, scientists are creating novel approaches for delivering these vaccinations to the body as well as for isolating and stimulating dendritic cells.
• Rising R&D Expenditure: Drug companies and government agencies are making significant investments in the study and creation of vaccines against dendritic cell cancer. In the upcoming years, it is anticipated that this investment will result in the development of new and improved vaccinations.

Key Challenges:

• Complexity of Manufacturing: The procedure of creating dendrite cell cancer vaccines is removing a patient's own immune cells, modifying them in a laboratory to target the cancer, and then reintroducing the immune cells to the patient. The production of the vaccinations is costly and time-consuming due to their complication.
• Limited Efficacy: Although some research has yielded encouraging results, dendrite cell cancer vaccinations is proving an unreliable treatment for various cancer types. To increase the effectiveness of these vaccinations, researchers are trying to improve their manufacturing process.
• Technological Advancements: Dendritic Cell Cancer Vaccine Market is boosting thanks to the technological advancement. Personalized vaccinations and the identification of patients most likely to benefit from this therapy are being facilitated by artificial intelligence (AI). Furthermore, genomics is making it possible to identify the best tumor targets, which will result in vaccines that work better. AI is also simplifying the intricate manufacturing process, which could lower costs and improve accessibility. The convergence of technological developments is opening doors for the development of potent and customized dendritic cell cancer vaccines.

Key Trends:

• Antigen Discovery: Genomic sequencing aids in the discovery of tumor-specific antigens, or immunological response-inducing chemicals. The development of more specialized vaccinations will result from AI's analysis and prediction of these antigens' capacity to stimulate the immune system.
• Heterogeneity of Tumors: The difference in the genetic makeup of tumors even among patients with the same form of cancer is increasing the demand for dendritic cell cancer vaccine.
• Combination of Expertise: While new firms frequently have cutting-edge technologies or distinctive antigen targets, established players provide knowledge in manufacturing, regulatory procedures, and clinical trials. They can overcome individual limits and accelerate the development of vaccines by combining their skills.

Global Dendritic Cell Cancer Vaccine Market Regional Analysis

Here is a more detailed regional analysis of the global Dendritic Cell Cancer Vaccine Market:

North America:

• According to Verified Market Research analyst, North America is expected to hold a major share in the global Dendritic Cell Cancer Vaccine Market. North America has dominated the Dendritic Cell Cancer Vaccine Market mostly due to large-scale research studies funded by pharmaceutical companies and university research institutes, as well as an extraordinary surge in the prevalence of cancer cases.
• North American region spend a lot on healthcare, more money may be allocated to the study and creation of cutting-edge cancer treatments, such as dendrite cell cancer vaccinations.
• North America has the biggest market share due to increased awareness of cancer treatment and the availability of well-developed healthcare infrastructure and research facilities.
• In North America, there is a growing awareness of cancer and accessible treatment choices, which could lead to increasing patient interest in tailored therapies like DC vaccines.

Asia Pacific:

• Several countries in Asia-Pacific are actively sponsoring cancer immunotherapy research and development, including DC vaccines. This involves sponsoring programs and reducing regulatory procedures. Countries are developing reimbursement schemes for approved DC vaccines, making them more available to patients.
• The evolving healthcare system present encouraging prospects for market growth. Even though the market is still developing in comparison to North America and Europe, a number of domestic and foreign companies are actively engaged in research partnerships and clinical trials. This strong activity suggests that the Asia Pacific area has enormous potential to influence the direction of cancer treatment using dendritic cells.
• There is a growing need for new treatment alternatives due to the increased incidence of cancer cases in nations like China and India. A climate that is conducive to the uptake of dendritic cell vaccines is being created by rising public knowledge of immunotherapy and government backing for it.

Global Dendritic Cell Cancer Vaccine Market: Segmentation Analysis

The Global Dendritic Cell Cancer Vaccine Market is segmented on the basis of Product Type, End-User, and Geography.

Dendritic Cell Cancer Vaccine Market, By Product Type

• Sipuleucel-T
• CreaVax

Based on Product Type, the market is bifurcated into Sipuleucel-T and CreaVax. Sipuleucel-T has the greatest share of the market among the others. The treatment of metastatic prostate cancer in males with sipuleucel-T is clinically authorized. with growing in acceptance. Sipuleucel-T, formerly known as Provenge, is now the market leader for dendritic cell cancer vaccines. This is due to its unique status as the first cancer immunotherapy to receive FDA approval.

• Sipuleucel-T is a targeted treatment for men with metastatic castration-resistant prostate cancer who are asymptomatic or very symptomatic. Even though there are currently other dendritic cell vaccines being developed, Sipuleucel-T's established presence and demonstrated efficacy are probably going to help it maintain its market share going forward.

Dendritic Cell Cancer Vaccine Market, By End-User

• Pediatric
• Adults

Based on End-User, the market is bifurcated into Pediatric and Adults. In the market for cancer vaccines against dendritic cell carcinoma, the adult category is dominant. Numerous factors contribute to this supremacy. First off, adult cancer incidence rates are often higher than those in youngsters. Second, adult malignancies such as lung, breast, and prostate cancers are the focus of a sizable fraction of current clinical trials for dendritic cell vaccines.

• The purpose of these trials is to assess the novel medicines' safety and effectiveness in adult patients. Furthermore, well-known competitors in the market, such as the company that created Sipuleucel-T (Provenge), focus mostly on adult patients. Although there is ongoing research into pediatric dendritic cell vaccines, the adult segment currently holds a dominant position in the market due to its established therapeutic choices and state of research.

Key Players

The "Global Dendritic Cell Cancer Vaccine Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are GlaxoSmithKline plc, 3M Company, Activartis, Batavia Bioservices, Argos Therapeutics, Sanpower Corporation, Elios Therapeutics, DanDrit Biotech, DCPrime, and ImmunoCellular Therapeutics.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

• Dendritic Cell Cancer Vaccine Market Recent Developments
• In September 2021, the development of immunotherapeutic techniques has allowed for the improvement of standard therapies' efficacy in the treatment of oncological disorders. Following the introduction of dendritic cell-based individualized therapeutic vaccines into clinical practice there was no significant advancement. The scope of use for dendritic cell (DC) vaccines has been expanded, and patient indicators for cancer have improved to a clearer understanding of dendritic cell biology and the adoption of novel techniques and agents for antigenic work. Furthermore, encouraging projections of DC vaccines application in broader clinical practice can be used due to their low toxicity in clinical trials.
• In June 2021, ASPAGNIITM was being used in dendritic cell (DC) based immunotherapy in cervical, ovarian cancer and will also be used in breast cancer. The process begins by extracting monocytes of white blood cell from the patient's blood. These monocytes are then transformed into dendritic cells which act as immune system messengers. The dendritic cells are equipped with a specific protein called ASPAGNIITM. This protein helps them recognize and target cancer cells expressing SPAG9. Finally, after being primed the dendritic cells are reintroduced into the body and there, they guide T cells to identify and destroy the cancer cells.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL DENDRITIC CELL CANCER VACCINE MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL DENDRITIC CELL CANCER VACCINE MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL DENDRITIC CELL CANCER VACCINE MARKET, PRODUCT TYPE

• 5.1 Overview
• 5.2 Sipuleucel-T
• 5.3 CreaVax

6 GLOBAL DENDRITIC CELL CANCER VACCINE MARKET, END-USER

• 6.1 Overview
• 6.2 Pediatric
• 6.3 Adults

7 GLOBAL DENDRITIC CELL CANCER VACCINE MARKET, BY GEOGRAPHY

• 7.1 Overview
• 7.2 North America
  • 7.2.1 U.S.
  • 7.2.2 Canada
  • 7.2.3 Mexico
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 U.K.
  • 7.3.3 France
  • 7.3.4 Rest of Europe
• 7.4 Asia Pacific
  • 7.4.1 China
  • 7.4.2 Japan
  • 7.4.3 India
  • 7.4.4 Rest of Asia Pacific
• 7.5 Rest of the World
  • 7.5.1 Latin America
  • 7.5.2 Middle East & Africa

8 GLOBAL DENDRITIC CELL CANCER VACCINE MARKET COMPETITIVE LANDSCAPE

• 8.1 Overview
• 8.2 Company Market Ranking
• 8.3 Key Development Strategies

9 COMPANY PROFILES

• 9.1 GlaxoSmithKline plc
  • 9.1.1 Overview
  • 9.1.2 Financial Performance
  • 9.1.3 Product Outlook
  • 9.1.4 Key Developments
• 9.2 3M Company
  • 9.2.1 Overview
  • 9.2.2 Financial Performance
  • 9.2.3 Product Outlook
  • 9.2.4 Key Developments
• 9.3 Activartis
  • 9.3.1 Overview
  • 9.3.2 Financial Performance
  • 9.3.3 Product Outlook
  • 9.3.4 Key Developments
• 9.4 Batavia Bioservices
  • 9.4.1 Overview
  • 9.4.2 Financial Performance
  • 9.4.3 Product Outlook
  • 9.4.4 Key Developments
• 9.5 Argos Therapeutics
  • 9.5.1 Overview
  • 9.5.2 Financial Performance
  • 9.5.3 Product Outlook
  • 9.5.4 Key Developments
• 9.6 Sanpower Corporation
  • 9.6.1 Overview
  • 9.6.2 Financial Performance
  • 9.6.3 Product Outlook
  • 9.6.4 Key Developments
• 9.7 Elios Therapeutics
  • 9.7.1 Overview
  • 9.7.2 Financial Performance
  • 9.7.3 Product Outlook
  • 9.7.4 Key Developments
• 9.8 DanDrit Biotech
  • 9.8.1 Overview
  • 9.8.2 Financial Performance
  • 9.8.3 Product Outlook
  • 9.8.4 Key Developments
• 9.9 DCPrime
  • 9.9.1 Overview
  • 9.9.2 Financial Performance
  • 9.9.3 Product Outlook
  • 9.9.4 Key Developments
• 9.10 ImmunoCellular Therapeutics
  • 9.10.1 Overview
  • 9.10.2 Financial Performance
  • 9.10.3 Product Outlook
  • 9.10.4 Key Developments

10 KEY DEVELOPMENTS

• 10.1 Product Launches/Developments
• 10.2 Mergers and Acquisitions
• 10.3 Business Expansions
• 10.4 Partnerships and Collaborations

11 Appendix

• 11.1 Related Research